• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Formulation Development Outsourcing Market Trends

    ID: MRFR/HC/8909-CR
    153 Pages
    Rahul Gotadki
    January 2021

    Formulation Development Outsourcing Market Research Report Information By Services (Pre Formulation Services and Formulation Optimization), By Dosage Form (Injectable, Oral, Topical, Inhaled, and Others), By Application (Oncology, Genetic Disorders, Neurology, Infectious Disease, Respiratory, Cardiovascular, and Others), By End User (Pharmaceutical and Biopharmaceutical, Government, and Academi...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Formulation Development Outsourcing Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Trends

    Key Emerging Trends in the Formulation Development Outsourcing Market

    One evident pattern is the rising interest for painless hemodynamic monitoring arrangements. Patients and medical services suppliers the same are progressively deciding on techniques that diminish pain and risk. Harmless advancements, like wearable gadgets and multipurpose screens, offer ongoing information without obtrusive systems, adding to patient accommodation and reliabity. The market is seeing a shift towards remote innovations for consistent information transmission and transparency. Hemodynamic monitoring systems with coordinated remote abilities empower medical care experts to remotely screen patients' important bodily functions, upgrading the general effectiveness of medical care conveyance. This pattern lines up with the more extensive development towards electronic health arrangements. With a developing accentuation on understanding driven care, hemodynamic monitoring systems are developing to give a more customized and custom-made approach. Adaptable settings, easy to use interfaces, and further developed patient commitment highlights are becoming norm in more up to date gadgets. These progressions engage patients as well as upgrade the general nature of medical care administrations. The market is seeing a flood in smart hemodynamic monitoring gadgets that influence artificial intelligence and AI calculations. These gadgets can dissect complex physiological information continuously, offering prescient experiences and helping medical care experts in early identification of likely issues. The coordination of smart advancements upgrades the symptomatic abilities of hemodynamic monitoring systems. In accordance with the more extensive telehealth pattern, hemodynamic monitoring systems are progressively being used for far off tolerant monitoring. This is especially significant for overseeing pre-determined conditions and postoperative consideration. Remote monitoring decreases the weight on medical services offices as well as considers constant observation, guaranteeing ideal mediations when required. The market for hemodynamic monitoring systems is growing all around the world, with a rising spotlight on developing markets. The interest for these systems is filling in emerging nations, driven by further developing medical services framework and a rising familiarity with the significance of consistent cardiovascular monitoring. Market players are decisively extending their scope to advance through these opportunities.

    Market Summary

    As per Market Research Future analysis, the Formulation Development Outsourcing Market is poised for significant growth, driven by increased R&D activities and a rising number of pharmaceutical companies outsourcing their services. The market is expected to expand from USD 10.8 Billion in 2025 to USD 23.57 Billion by 2035, reflecting a CAGR of 8.12%. The demand for generics and biosimilars, particularly following patent expirations, is a key growth driver. The oncology segment leads in revenue, while the injectable dosage form is the fastest-growing category due to its high bioavailability. North America holds the largest market share, accounting for USD 9.99 Billion in 2024, with Europe following closely behind.

    Key Market Trends & Highlights

    The market is witnessing several key trends that are shaping its growth trajectory.

    • Market Size in 2024: USD 9.99 Billion.
    • Projected Market Size in 2034: USD 21.8 Billion.
    • CAGR from 2025 to 2035: 8.12%.
    • North America Market Share in 2022: 45.80%.

    Market Size & Forecast

    2024 Market Size USD 9.99 Billion
    2035 Market Size USD 23.57 Billion
    CAGR (2025-2035) 8.12%
    North America Market Share in 2022 USD 3.61 Billion.

    Major Players

    Key players include Charles River Laboratories (US), Laboratory Corporation of America (US), Intertek (US), and Catalent Inc. (US).

    Market Trends

    Demand is high in response to the increased R&D activities to propel market growth.

    The growing number of pharmaceutical and biopharmaceutical enterprises outsourcing their services. The growing trend of patent protection expiration of major drugs is driving the market growth. For instance, according to an update in 2021 by the Generics and Biosimilar Initiative, as an element of ongoing activities to enhance the quality of generics and provide an efficient and competitive generics need, the Korean Ministry of Food and Drug Safety (MFDS) declared that 158 patents for pharmaceutical products were expected to expire in 2021.

    The MFDS's Green List declares that 44 of the patents will be ready for rapid generics entry, having no additional patents on the products concerned. Thus, this increases the demand for formulation development outsourcing for substitute candidates, thereby contributing to the market CAGR.

    However, the growing demand for overcoming the risk associated with formulation development outsourcing further contributes to market growth. As per the report by IQVIA, in developed countries, the demand for generics and biosimilars is expected to grow, improving the medicine spending in these countries. This is likely to improve the demand for formulation development outsourcing of generics and biosimilar post-pandemic. Furthermore, despite the COVID-19 pandemic's immediate concerns, the pharmaceutical industry's quest for innovative and effective therapeutics continues to drive longer-term growth, and clinical research for new and existing COVID-19 therapies continues to expand.

    Thus, it is anticipated that this aspect will accelerate formulation development outsourcing market revenue globally.

    .webp

    The increasing complexity of drug formulations and the rising demand for cost-effective solutions are driving pharmaceutical companies to increasingly rely on external partners for formulation development.

    U.S. Food and Drug Administration (FDA)

    Formulation Development Outsourcing Market Market Drivers

    Focus on Speed to Market

    The focus on speed to market is a significant driver in the Global Formulation Development Outsourcing Market Industry. In a highly competitive pharmaceutical landscape, companies are under pressure to expedite the development and launch of new products. Outsourcing formulation development allows firms to leverage the capabilities of specialized providers, thereby accelerating the overall development timeline. This urgency is reflected in the market's projected growth, with an expected increase to 9.97 USD Billion in 2024. As companies prioritize rapid product development, the outsourcing of formulation services is likely to become an increasingly attractive option.

    Market Growth Projections

    The Global Formulation Development Outsourcing Market Industry is poised for substantial growth, with projections indicating a rise from 9.97 USD Billion in 2024 to 23.6 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 8.14% from 2025 to 2035. Such figures reflect the increasing reliance of pharmaceutical companies on outsourcing to enhance efficiency, reduce costs, and meet regulatory demands. The market's expansion is indicative of broader trends in the pharmaceutical sector, where innovation and specialization are becoming essential for success.

    Rising Demand for Biologics

    The Global Formulation Development Outsourcing Market Industry experiences a notable increase in demand for biologics, which are complex molecules derived from living organisms. This trend is driven by the growing prevalence of chronic diseases and the need for innovative therapies. As pharmaceutical companies focus on developing biologics, outsourcing formulation development becomes a strategic choice to leverage specialized expertise and reduce time to market. The market for biologics is projected to grow significantly, contributing to the overall growth of the Global Formulation Development Outsourcing Market, which is expected to reach 9.97 USD Billion in 2024 and 23.6 USD Billion by 2035.

    Cost Efficiency and Resource Optimization

    Cost efficiency remains a critical driver in the Global Formulation Development Outsourcing Market Industry. By outsourcing formulation development, companies can significantly reduce operational costs associated with in-house development. This approach allows organizations to allocate resources more effectively, focusing on core competencies while leveraging the expertise of specialized service providers. As the market evolves, the potential for cost savings becomes increasingly attractive, particularly for small and medium-sized enterprises. The anticipated compound annual growth rate of 8.14% from 2025 to 2035 underscores the financial advantages that outsourcing can offer, further propelling the growth of the Global Formulation Development Outsourcing Market.

    Regulatory Compliance and Quality Assurance

    Regulatory compliance and quality assurance are paramount in the Global Formulation Development Outsourcing Market Industry. As regulatory bodies impose stringent guidelines on drug development, companies must ensure that their formulations meet these standards. Outsourcing formulation development to experienced service providers can facilitate adherence to regulatory requirements, thereby mitigating risks associated with non-compliance. This necessity for quality assurance drives pharmaceutical companies to seek external expertise, fostering growth in the outsourcing market. The increasing complexity of regulations further emphasizes the importance of outsourcing, as companies strive to maintain high-quality standards in their formulations.

    Technological Advancements in Drug Development

    Technological advancements play a pivotal role in shaping the Global Formulation Development Outsourcing Market Industry. Innovations in drug formulation technologies, such as nanotechnology and 3D printing, enhance the efficiency and effectiveness of drug development processes. These advancements enable companies to create more effective formulations with improved bioavailability and stability. As pharmaceutical firms increasingly adopt these technologies, the demand for specialized formulation development services is likely to rise. This trend is expected to contribute to the market's growth trajectory, with projections indicating a rise to 23.6 USD Billion by 2035, reflecting the industry's adaptation to cutting-edge technologies.

    Market Segment Insights

    Formulation Development Outsourcing Services Insights

    The market segments of formulation development outsourcing, based on services, includes pre-formulation services and formulation optimization. The formulation optimization segment held the majority market share in 2022 in the. Formulation development outsourcing is required in each stage of clinical trials, and the number of clinical studies has increased significantly over the years. According to ClinicalTrials.gov, over 293,251 research studies were registered in 2019, while the number of registered studies climbed to 362,503 in 2021. However, pre-formulation services are the fastest-growing category because the growing number of clinical studies is likely to positively impact the market growth for formulation development outsourcing.

    Formulation Development Outsourcing Dosage Form Insights

    The formulation development outsourcing market segmentation, based on dosage form, includes injectable, oral, topical, inhaled, and others. The oral segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2030. Oral formulations are used in treating common diseases such as migraines, fever, infectious diseases, and diabetes, among others. Oral formulations are self-administering and do not require a trained physician for drug administration.

    However, the injectable is the fastest-growing category over the forecast period due to the high bioavailability of injectable formulations leading to the immediate onset of action is the prime factor for its fastest growth.

    Figure 2: Formulation Development Outsourcing Market, by Form, 2022 & 2030 (USD Billion) 

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Formulation Development Outsourcing Application Insights

    The formulation development outsourcing market data, based on application, includes oncology, genetic disorders, neurology, infectious disease, respiratory, cardiovascular, and others. The oncology segment dominated the market revenue of formulation development outsourcing in 2022 and is projected to be the faster-growing category over the forecast period, 2022-2030. Cancer is one of the primary causes of demise globally, which has significantly led to the demand for new cancer therapies. According to ClinicalTrials.gov, as of June 6, 2022, over 29,662 studies were in the active stage for cancer.

    The high number of clinical studies for cancer is likely to improve the demand for formulation development outsourcing services for cancer treatment. However, respiratory is the fastest-growing category due to the growing number of people suffering from respiratory problems.

    Formulation Development Outsourcing End User Insights

    The market data of ormulation development outsourcing, based on end users, include pharmaceutical and biopharmaceutical, government, and academic institutes. The academic institutes' segment dominated the market revenue of formulation development outsourcing in 2022 due to growing R&D costs. However, pharmaceutical and biopharmaceutical is the fastest-growing category due to the rising number of pharmaceutical and biopharmaceutical companies outsourcing their services.

    Get more detailed insights about Formulation Development Outsourcing Market Research Report - Global Forecast till 2034

    Regional Insights

    By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America formulation development outsourcing market accounted for USD 3.61 billion in 2022, with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. This can be attributed to the increasing burden of chronic diseases and the existence of key players in the region, especially in the US.

    As most of the prominent drugs are in the stage of patent expiration, major players are involved in novel drug formulation development outsourcing, which may drive market growth in the region.

    Further, the major countries studied in the market report are: The U.S, Germany, Canada, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 3: FORMULATION DEVELOPMENT OUTSOURCING MARKET SHARE BY REGION 2022 (%) 

    FORMULATION DEVELOPMENT OUTSOURCING MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe formulation development outsourcing market accounts for the second-largest market share. This is attributed to the presence of a significant number of CROs offering cost-effective formulation developing services, which is one of the major reasons for the largest market share. Moreover, UK market of formulation development outsourcing held the largest market share, and the Germany market of formulation development outsourcing was the fastest-growing market in the region.

    The Asia-Pacific formulation development outsourcing market is expected to enhance at the fastest CAGR from 2023 to 2030. Several market players implement strategic initiatives, thereby contributing to market growth. For instance, in October 2021, the Department of Pharmaceuticals (India) drafted new rules to reduce the time required for the approval of innovative products by at least 50% within the next two years, to improve the R&D activities in the country. Such initiatives will likely improve the demand for formulation development outsourcing services in the country.

    Further, the China market of formulation development outsourcing held the largest market share, and the India market of formulation development outsourcing was the fastest-growing market in the region.

    Key Players and Competitive Insights

    Key market players are spending a huge amount of money on R&D to expand their product lines, which will assist the market of formulation development outsourcing to grow even more. Market participants are also taking several strategic initiatives to expand their worldwide footprint, with key market developments including new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the formulation development outsourcing industry must provide cost-effective items to expand and survive in an increasingly competitive and increasing market environment.

    One of the major business strategies manufacturers adopts in the formulation development outsourcing industry to benefit clients and enhance the market sector is manufacturing locally to reduce operating costs. In recent years, the formulation development outsourcing industry has provided drugs with some of the most significant advances. In the formulation development outsourcing market players such as Charles Rover laboratories (US), Laboratory Corporation of America (US), Intertek (US) and others are working on enhancing the market demand by investing in research and formulation development outsourcing activities.

    Recro Pharma (REPR) is a specialty pharmaceutical firm that operates through two business divisions. An Acute Care division and a revenue-generating CDMO division. Each of these divisions is deemed a reportable segment for financial reporting purposes. In January 2022, Recro Pharma Inc., an agreement development and manufacturing firm dedicated to solving difficult formulation and manufacturing challenges, especially in small molecule therapeutic development, was awarded a new formulation development and manufacturing contract from a critical department of the US government.

    Coriolis is one of the leaders in formulation R&D of (bio)pharmaceutical drugs and vaccines and a globally operating analytical service provider. Their motivation is to allow the development of innovative medicines by performing outstanding biopharmaceutical research to enhance the quality of life for humankind. In January 2022, Coriolis Pharma opened new ATMP Formulation Development Facilities. The new facilities are located near Coriolis’ headquarters in Martinsried, which will significantly increase Coriolis’ capabilities for ATMP development.

    Key Companies in the Formulation Development Outsourcing Market market include

    Industry Developments

    • Q2 2024: Catalent Expands Formulation Development Capabilities with New Facility in Kansas City Catalent announced the opening of a new formulation development and manufacturing facility in Kansas City, Missouri, aimed at increasing its capacity for oral and injectable drug product development.
    • Q1 2024: Thermo Fisher Scientific Acquires Contract Development and Manufacturing Organization (CDMO) for $1.7 Billion Thermo Fisher Scientific completed the acquisition of a leading CDMO specializing in formulation development, expanding its service offerings for pharmaceutical and biotech clients.
    • Q2 2024: Lonza Announces Strategic Partnership with BioNTech for mRNA Formulation Development Lonza and BioNTech entered a multi-year partnership to co-develop and manufacture mRNA-based drug formulations, enhancing both companies' capabilities in advanced therapeutics.
    • Q3 2024: Pfizer Opens New Formulation Development Center in Ireland Pfizer inaugurated a new state-of-the-art formulation development center in Cork, Ireland, to support its growing pipeline of complex oral and injectable medicines.
    • Q2 2024: Recipharm Acquires Arranta Bio to Expand Formulation Development Services Recipharm acquired Arranta Bio, a specialist in advanced formulation and process development for biologics, strengthening its position in the outsourced development market.
    • Q1 2024: Aenova Group Launches New High-Potency Formulation Development Suite in Germany Aenova Group announced the launch of a new high-potency formulation development suite at its Regensburg site, expanding its capabilities for oncology and specialty drug products.
    • Q2 2025: WuXi AppTec Secures Major Formulation Development Contract with European Pharma WuXi AppTec signed a multi-year contract with a top European pharmaceutical company to provide end-to-end formulation development and manufacturing services.
    • Q1 2025: Lonza Invests $100 Million in New Formulation Development Facility in Switzerland Lonza announced a $100 million investment to build a new formulation development and manufacturing facility in Visp, Switzerland, to meet rising demand for outsourced services.
    • Q2 2024: Syngene International Wins Formulation Development Outsourcing Contract from US Biotech Syngene International secured a significant contract to provide formulation development and analytical services for a US-based biotechnology company’s new drug candidate.
    • Q3 2024: Samsung Biologics Expands Formulation Development Capabilities with New Suite Samsung Biologics launched a new formulation development suite at its Songdo facility, enhancing its ability to support clients with biologics and biosimilar drug products.
    • Q2 2025: Pfizer Appoints New Head of Formulation Development to Lead Global Expansion Pfizer announced the appointment of Dr. Maria Lopez as the new global head of formulation development, tasked with driving innovation and expansion in outsourced services.
    • Q1 2025: Thermo Fisher Scientific Launches AI-Driven Formulation Development Platform Thermo Fisher Scientific introduced a new AI-powered platform designed to accelerate and optimize formulation development for pharmaceutical and biotech clients.

    Future Outlook

    Formulation Development Outsourcing Market Future Outlook

    The Global Formulation Development Outsourcing Market is poised for growth at 8.12% CAGR from 2024 to 2034, driven by technological advancements, increasing R&D investments, and the demand for specialized formulations.

    New opportunities lie in:

    • Leverage AI-driven analytics to enhance formulation efficiency and reduce time-to-market.
    • Expand service offerings to include personalized medicine formulations for niche markets.
    • Invest in sustainable practices to attract environmentally conscious clients and improve brand reputation.

    By 2035, the market is expected to achieve substantial growth, reflecting robust demand and innovation.

    Market Segmentation

    Formulation Development Outsourcing End User Outlook (USD Billion, 2019-2030)

    • Pharmaceutical and Biopharmaceutical
    • Government
    • Academic Institutes

    Formulation Development Outsourcing Services Outlook (USD Billion, 2019-2030)

    • Pre Formulation Services
    • Formulation Optimization

    Formulation Development Outsourcing Application Outlook (USD Billion, 2019-2030)

    • Oncology
    • Genetic Disorders
    • Neurology
    • Infectious Disease
    • Respiratory
    • Cardiovascular
    • Others

    Formulation Development Outsourcing Dosage Form Outlook (USD Billion, 2019-2030)

    • Injectable
    • Oral
    • Topical
    • Inhaled
    • Others

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024    9.99 (USD Billion)
    Market Size 2025   10.80 (USD Billion)
    Market Size 2035 23.57 (USD Billion)
    Compound Annual Growth Rate (CAGR) 8.12% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Services, Dosage Form, Application, End User and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Charles Rover laboratories (US), Reddy’s Laboratories (India), Lonza Group AG(Switzerland), Aizant Drug Research Solutions Pvt. Ltd.(US), Syngene International Limited (India), and Irisys LLC Laboratory Corporation of America Holdings (US)
    Key Market Opportunities The growing demand for new drugs owing to the high burden of chronic
    Key Market Dynamics The increased R&D costs

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What is the projected growth of the Formulation Development Outsourcing market?

    The Formulation Development Outsourcing market is the expected increase in total market value of 23.57 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

    What is the size of the Formulation Development Outsourcing market?

    Formulation Development Outsourcing market size was valued at approximately 9.99 billion USD in 2024. This figure will reach 23.57 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

    What is the CAGR of the Formulation Development Outsourcing market?

    Formulation Development Outsourcing market is expected to grow at a CAGR of 8.12% between 2025 and 2035.

    How much will the Formulation Development Outsourcing market be worth by 2035?

    Formulation Development Outsourcing market is expected to be worth of 23.57 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

    How will the Formulation Development Outsourcing market perform over the next 10 years?

    Over the next 10 years the Formulation Development Outsourcing market is expected to shift from usd billion 9.99 to 23.57 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

    Which region held the largest market share in the formulation development outsourcing market?

    North America had the largest share of the market

    Who are the key players in the market for formulation development outsourcing?

    The key players in the market are Charles Rover laboratories (US), Reddy’s Laboratories (India), Catalent Inc. (US), Thermo Fischer Scientific Inc. (US), and Emergent Biosolutions Inc.(US).

    Which services led the formulation development outsourcing market?

    The formulation optimization category dominated the market in 2024.

    1. EXECUTIVE SUMMARY
      1. MARKET SYNOPSIS 16
    2. MARKET INTRODUCTION
      1. SCOPE OF THE STUDY 17
      2. RESEARCH OBJECTIVE 17
      3. LIST OF ASSUMPTIONS
      4. & LIMITATIONS 17
    3. RESEARCH METHODOLOGY
      1. OVERVIEW 19
      2. 3.2
      3. DATA MINING 19
      4. SECONDARY RESEARCH 20
      5. PRIMARY RESEARCH 21
        1. BREAKDOWN OF
      6. 3.4.1
      7. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21
      8. PRIMARY RESPONDENTS 22
      9. FORECASTING TECHNIQUES 23
      10. RESEARCH METHODOLOGY
        1. BOTTOM-UP APPROACH 24
        2. TOP-DOWN
      11. FOR MARKET SIZE ESTIMATION 24
      12. APPROACH 25
      13. DATA TRIANGULATION 25
      14. VALIDATION 25
    4. GLOBAL
    5. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES
      1. INTRODUCTION 26
      2. PREFORMULATION SERVICES 27
        1. FORMULATION DISCOVERY 28
        2. ANALYTICAL SERVICES 29
      3. 4.2.2
      4. PRECLINICAL SERVICES 28
      5. FORMULATION OPTIMIZATION
        1. PHASE I 30
        2. PHASE II 30
        3. PHASE III 31
      6. 29
      7. 4.3.4
      8. PHASE IV 31
    6. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE
      1. FORM
      2. INTRODUCTION 32
      3. INJECTABLE 34
      4. ORAL 34
      5. TOPICAL
      6. 35
      7. INHALED 35
      8. OTHERS 36
    7. GLOBAL FORMULATION DEVELOPMENT
    8. OUTSOURCING MARKET, BY APPLICATION
      1. INTRODUCTION 37
      2. ONCOLOGY 39
      3. GENETIC DISORDERS 40
      4. NEUROLOGY 40
      5. INFECTIOUS DISEASES 41
      6. RESPIRATORY 41
      7. CARDIOVASCULAR 42
      8. OTHERS 42
      9. 7
    9. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER
      1. INTRODUCTION
      2. 43
      3. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 44
      4. GOVERNMENT
      5. & ACADEMIC INSTITUTES 44
    10. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING
    11. MARKET, BY REGION
      1. INTRODUCTION 45
      2. AMERICAS 46
        1. NORTH
        2. LATIN AMERICA 55
      3. AMERICA 48
      4. EUROPE 58
        1. WESTERN EUROPE 61
        2. EASTERN EUROPE 75
      5. 8.3.1.2
      6. FRANCE 65
      7. 8.3.1.6
      8. REST OF WESTERN EUROPE 73
      9. ASIA-PACIFIC 78
        1. JAPAN 80
        2. CHINA 82
        3. INDIA 84
        4. AUSTRALIA 86
        5. SOUTH KOREA 88
        6. REST OF ASIA-PACIFIC 90
      10. MIDDLE EAST &
        1. MIDDLE EAST 95
        2. AFRICA 97
      11. AFRICA 93
    12. COMPETITIVE
      1. LANDSCAPE
      2. OVERVIEW 100
      3. MARKET SHARE ANALYSIS 100
      4. MAJOR
    13. GROWTH STRATEGY IN THE GLOBAL FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET
      1. 101
      2. THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL
      3. FORMULATION DEVELOPMENT OUTSOURCING SERVICES MARKET 102
      4. KEY DEVELOPMENT
      5. ANALYSIS 102
      6. KEY DEVELOPMENTS & GROWTH STRATEGIES 103
        1. ACQUISITION
        2. EXPANSION 104
        3. FINANCIAL MATRIX 104
      7. ACTIVITIES 103
      8. 9.6.4
      9. R&D EXPENDITURE 104
    14. COMPANY ANALYSIS
      1. CHARLES RIVER LABORATORIES
      2. 105
      3. AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 106
      4. CATALENT,
      5. INC. 108
      6. LABORATORY CORPORATION OF AMERICA 109
      7. SYNGENE INTERNATIONAL
      8. LTD. 110
      9. IRISYS, LLC 111
      10. INTERTEK 112
      11. PIRAMAL ENTERPRISES
      12. LTD. 113
      13. QUOTIENT SCIENCES 114
      14. PATHEON (THERMO FISHER SCIENTIFIC)
      15. 115
      16. EMERGENT BIOSOLUTIONS INC. 116
      17. LONZA 117
      18. PCI
      19. 118
      20. DR. REDDY’S LABORATORIES LTD. 118
    15. COMPANY PROFILES
      1. AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED 119
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW 119
        3. PRODUCTS/SERVICES OFFERED 119
        4. KEY DEVELOPMENTS 121
        5. SWOT ANALYSIS 122
        6. KEY STRATEGIES
      2. 119
      3. 122
      4. IRISYS, INC. 123
        1. COMPANY OVERVIEW 123
        2. FINANCIAL
        3. PRODUCTS/SERVICES OFFERED 123
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS 125
        6. KEY STRATEGIES 125
      5. OVERVIEW 123
      6. 124
      7. CHARLES
        1. COMPANY OVERVIEW 126
        2. PRODUCTS OFFERED 127
        3. KEY DEVELOPMENTS
        4. SWOT ANALYSIS 128
        5. KEY STRATEGIES 128
      8. RIVER LABORATORIES INTERNATIONAL, INC. 126
      9. 11.3.2
      10. FINANCIAL OVERVIEW 126
      11. 128
      12. INTERTEK
        1. COMPANY OVERVIEW 129
        2. FINANCIAL OVERVIEW 129
        3. PRODUCTS/SERVICES OFFERED 130
        4. KEY DEVELOPMENTS 131
        5. KEY STRATEGIES 131
      13. GROUP PLC 129
      14. 11.4.5
      15. SWOT ANALYSIS 131
      16. CATALENT, INC. 132
        1. COMPANY OVERVIEW 132
        2. FINANCIAL OVERVIEW 132
        3. PRODUCTS/SERVICES
        4. KEY DEVELOPMENTS 134
        5. SWOT ANALYSIS 134
      17. OFFERED 133
      18. 11.5.4
      19. KEY STRATEGIES 135
      20. SYGENE INTERNATIONAL LIMITED 136
        1. COMPANY
        2. FINANCIAL OVERVIEW 136
        3. PRODUCTS/SERVICES OFFERED
        4. KEY DEVELOPMENTS 138
        5. SWOT ANALYSIS 139
        6. KEY
      21. OVERVIEW 136
      22. 137
      23. STRATEGIES 139
      24. LABORATORY CORPORATION OF AMERICA HOLDINGS 140
        1. FINANCIAL OVERVIEW 140
        2. PRODUCTS/SERVICES
        3. KEY DEVELOPMENTS 141
        4. SWOT ANALYSIS 142
      25. 11.7.1
      26. COMPANY OVERVIEW 140
      27. OFFERED 141
      28. 11.7.6
      29. KEY STRATEGIES 142
      30. PATHEON (THERMO FISHER SCIENTIFIC) 143
        1. FINANCIAL OVERVIEW 143
        2. PRODUCTS/SERVICES
        3. KEY DEVELOPMENTS 145
        4. SWOT ANALYSIS 145
      31. 11.8.1
      32. COMPANY OVERVIEW 143
      33. OFFERED 144
      34. 11.8.6
      35. KEY STRATEGIES 146
      36. QUOTIENT SCIENCES 147
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW 147
        3. PRODUCTS/SERVICES OFFERED 147
        4. KEY DEVELOPMENTS 148
        5. SWOT ANALYSIS 148
        6. KEY STRATEGIES
      37. 147
      38. 148
      39. EMERGENT BISOLUTIONS INC. 149
        1. COMPANY OVERVIEW 149
        2. FINANCIAL OVERVIEW 149
        3. PRODUCTS/SERVICES OFFERED 149
        4. SWOT ANALYSIS 150
        5. KEY STRATEGIES
      40. 11.10.4
      41. KEY DEVELOPMENTS 150
      42. 150
    16. APPENDIX
      1. REFERENCES 151
      2. RELATED REPORTS 152
    17. LIST OF TABLES
    18. LIST OF ASSUMPTIONS & LIMITATIONS 17
    19. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022-2030
      1. (USD MILLION) 27
    20. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE, 2022-2030
      2. (USD MILLION) 27
      3. TABLE
    21. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES,
      1. BY REGION, 2022-2030
      2. (USD MILLION) 27
    22. GLOBAL FORMULATION DEVELOPMENT
    23. OUTSOURCING MARKET, FOR FORMULATION DISCOVERY, BY REGION, 2022-2030
      1. (USD MILLION)
      2. 28
    24. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PRECLINICAL
      1. SERVICES, BY REGION, 2022-2030
      2. (USD MILLION) 28
    25. GLOBAL FORMULATION
    26. DEVELOPMENT OUTSOURCING MARKET, FOR ANALYTICAL SERVICES, BY REGION, 2022-2030
      1. (USD MILLION) 29
    27. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE, 2022-2030
      2. (USD MILLION) 29
      3. TABLE
    28. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY REGION, 2022-2030
      2. (USD MILLION) 29
    29. GLOBAL FORMULATION DEVELOPMENT
    30. OUTSOURCING MARKET, FOR PHASE I, BY REGION, 2022-2030 (USD MILLION) 30
      1. TABLE
    31. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PHASE II, BY REGION, 2022-2030
      1. (USD MILLION) 30
    32. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PHASE III, BY REGION, 2022-2030 (USD MILLION) 31
    33. GLOBAL FORMULATION
    34. DEVELOPMENT OUTSOURCING MARKET, FOR PHASE IV, BY REGION, 2022-2030 (USD MILLION)
      1. 31
    35. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM,
    36. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING
    37. MARKET, FOR INJECTABLE, BY REGION, 2022-2030 (USD MILLION) 34
    38. GLOBAL
    39. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR ORAL, BY REGION, 2022-2030 (USD
      1. MILLION) 34
    40. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR
      1. TOPICAL, BY REGION, 2022-2030 (USD MILLION) 35
    41. GLOBAL FORMULATION
    42. DEVELOPMENT OUTSOURCING MARKET, FOR INHALED, BY REGION, 2022-2030 (USD MILLION)
      1. 35
    43. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR OTHERS,
      1. BY REGION, 2022-2030 (USD MILLION) 36
    44. GLOBAL FORMULATION DEVELOPMENT
    45. OUTSOURCING MARKET, BY APPLICATION, 2022-2030 (USD MILLION) 39
    46. GLOBAL
    47. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR ONCOLOGY, BY REGION, 2022-2030 (USD
      1. MILLION) 39
    48. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR
      1. GENETIC DISORDERS, BY REGION, 2022-2030
      2. (USD MILLION) 40
    49. GLOBAL
    50. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR NEUROLOGY, BY REGION, 2022-2030
      1. (USD MILLION) 40
    51. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR INFECTIOUS DISEASES, BY REGION, 2022-2030
      2. (USD MILLION) 41
      3. TABLE 25
    52. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR RESPIRATORY, BY REGION, 2022-2030
      1. (USD MILLION) 41
    53. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR CARDIOVASCULAR, BY REGION, 2022-2030 (USD MILLION) 42
    54. GLOBAL FORMULATION
    55. DEVELOPMENT OUTSOURCING MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 42
    56. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022-2030
      1. (USD MILLION) 44
    57. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PHARMACEUTICAL & BIOPHARMACEUTICAL
      2. COMPANIES, BY REGION, 2022-2030
      3. (USD MILLION) 44
    58. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR GOVERNMENT & ACADEMIC INSTITUTES, BY REGION
      2. , 2022-2030 (USD MILLION)
      3. 44
    59. GLOBAL: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY REGION,
    60. AMERICAS: FORMULATION DEVELOPMENT
    61. OUTSOURCING MARKET, BY REGION, 2022–2030 (USD MILLION) 46
    62. AMERICAS:
    63. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION)
      1. 46
    64. AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION
      1. SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 47
    65. AMERICAS:
    66. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE
      1. (USD MILLION) 47
    67. AMERICAS: FORMULATION DEVELOPMENT
    68. OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 47
      1. TABLE
    69. AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 48
    70. AMERICAS: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 48
    71. NORTH AMERICA: FORMULATION
    72. DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 48
    73. NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    74. NORTH AMERICA: FORMULATION DEVELOPMENT
    75. OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE
      1. MILLION) 49
    76. NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE
    77. NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE
      1. FORM, 2022–2030 (USD MILLION) 50
    78. NORTH AMERICA: FORMULATION
    79. DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 50
    80. NORTH AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER,
    81. US: FORMULATION DEVELOPMENT OUTSOURCING
    82. MARKET, BY SERVICES, 2022–2030 (USD MILLION) 51
    83. US: FORMULATION
    84. DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD MILLION) 51
    85. US: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      2. (USD MILLION) 52
    86. US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 52
    87. US: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY
      1. APPLICATION, 2022–2030 (USD MILLION) 53
    88. US: FORMULATION DEVELOPMENT
    89. OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 53
      1. TABLE 52
    90. CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 53
    91. CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 54
      3. TABLE
    92. CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY PHASE 2022–2030
      2. (USD MILLION) 54
    93. CANADA: FORMULATION
    94. DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 54
    95. CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 55
    96. CANADA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 55
    97. LATIN AMERICA: FORMULATION
    98. DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 55
    99. LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION
      1. SERVICES, BY TYPE
    100. LATIN AMERICA:
    101. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE
    102. LATIN AMERICA: FORMULATION DEVELOPMENT
    103. OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 56
      1. TABLE
    104. LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 57
    105. LATIN AMERICA: FORMULATION DEVELOPMENT OUTSOURCING
    106. MARKET, BY END USER, 2022–2030 (USD MILLION) 57
    107. EUROPE FORMULATION
    108. DEVELOPMENT OUTSOURCING MARKET, BY REGION, 2022-2030 (USD MILLION) 58
      1. TABLE
    109. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 58
    110. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 58
      3. TABLE
    111. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY PHASE 2022–2030
      2. (USD MILLION) 59
    112. EUROPE: FORMULATION
    113. DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 59
    114. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 60
    115. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 60
    116. WESTERN EUROPE FORMULATION
    117. DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY , 2022-2030 (USD MILLION) 61
      1. TABLE
    118. WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 61
    119. WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING
    120. MARKET, FOR PREFORMULATION SERVICES, BY TYPE
      1. 61
    121. WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR
      1. FORMULATION OPTIMIZATION, BY PHASE
      2. TABLE
    122. WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 62
    123. WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING
    124. MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 63
    125. WESTERN EUROPE:
    126. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION)
      1. 63
    127. GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    128. GERMANY: FORMULATION DEVELOPMENT
    129. OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD
      2. MILLION) 64
    130. GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR
      1. FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      2. (USD MILLION) 64
      3. TABLE
    131. GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 64
    132. GERMANY: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY APPLICATION, 2022–2030 (USD MILLION) 65
    133. GERMANY: FORMULATION
    134. DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 65
    135. FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 65
    136. FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 66
      3. TABLE
    137. FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY PHASE 2022–2030
      2. (USD MILLION) 66
    138. FRANCE: FORMULATION
    139. DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 66
    140. FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 67
    141. FRANCE: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 67
    142. UK: FORMULATION DEVELOPMENT
    143. OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 67
      1. TABLE 91
      2. UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY
      3. TYPE 2022–2030
      4. (USD MILLION) 68
    144. UK: FORMULATION DEVELOPMENT
    145. OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      1. (USD
      2. MILLION) 68
    146. UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE
      1. FORM, 2022–2030 (USD MILLION) 68
    147. UK: FORMULATION DEVELOPMENT
    148. OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 69
      1. TABLE
    149. UK: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 69
    150. ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY SERVICES, 2022–2030 (USD MILLION) 69
    151. ITALY: FORMULATION DEVELOPMENT
    152. OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD
      2. MILLION) 70
    153. ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR
      1. FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      2. (USD MILLION) 70
      3. TABLE
    154. ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 70
    155. ITALY: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY APPLICATION, 2022–2030 (USD MILLION) 71
    156. ITALY: FORMULATION
    157. DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 71
    158. SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 71
    159. SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 72
      3. TABLE
    160. SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY PHASE 2022–2030
      2. (USD MILLION) 72
    161. SPAIN: FORMULATION
    162. DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 72
    163. SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 73
    164. SPAIN: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 73
    165. REST OF WESTERN EUROPE:
    166. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION)
      1. 73
    167. REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES,
      2. BY TYPE 2022–2030 (USD MILLION) 74
      3. TABLE
    168. REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION
      1. OPTIMIZATION,
      2. BY PHASE 2022–2030 (USD MILLION) 74
    169. REST
    170. OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 74
    171. REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT
    172. OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 75
      2. TABLE
    173. REST OF WESTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER,
    174. EASTERN EUROPE: FORMULATION DEVELOPMENT
    175. OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 75
      1. TABLE 115
      2. EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES,
      3. BY TYPE
    176. EASTERN EUROPE: FORMULATION
    177. DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE
      1. (USD MILLION) 76
    178. EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING
    179. MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 76
    180. EASTERN
    181. EUROPE: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 77
    182. EASTERN EUROPE: FORMULATION DEVELOPMENT OUTSOURCING
    183. MARKET, BY END USER, 2022–2030 (USD MILLION) 77
    184. ASIA-PACIFIC:
    185. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
      1. 78
    186. ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    187. ASIA-PACIFIC: FORMULATION DEVELOPMENT
    188. OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD
      2. MILLION) 78
    189. ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE
    190. ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE
      1. FORM, 2022–2030 (USD MILLION) 79
    191. ASIA-PACIFIC: FORMULATION
    192. DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 80
    193. ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER,
    194. JAPAN: FORMULATION DEVELOPMENT OUTSOURCING
    195. MARKET, BY SERVICES, 2022–2030 (USD MILLION) 80
    196. JAPAN: FORMULATION
    197. DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD MILLION) 81
    198. JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      2. (USD MILLION) 81
    199. JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 81
    200. JAPAN: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY APPLICATION, 2022–2030 (USD MILLION) 82
    201. JAPAN: FORMULATION
    202. DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 82
    203. CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030
      1. (USD MILLION) 82
    204. CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 83
      3. TABLE
    205. CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      1. BY PHASE 2022–2030
      2. (USD MILLION) 83
    206. CHINA: FORMULATION
    207. DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 83
    208. CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030
      1. (USD MILLION) 84
    209. CHINA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 84
    210. INDIA: FORMULATION
    211. DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION) 84
    212. INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION
      1. SERVICES, BY TYPE 2022–2030
      2. (USD MILLION) 85
    213. INDIA: FORMULATION
    214. DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      1. (USD MILLION) 85
    215. INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY DOSAGE FORM, 2022–2030 (USD MILLION) 85
    216. INDIA: FORMULATION
    217. DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 86
    218. INDIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 86
    219. AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY SERVICES, 2022–2030 (USD MILLION) 86
    220. AUSTRALIA: FORMULATION
    221. DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD MILLION) 87
    222. AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING
    223. MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      1. (USD MILLION)
      2. 87
    224. AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE
      1. FORM, 2022–2030 (USD MILLION) 87
    225. AUSTRALIA: FORMULATION DEVELOPMENT
    226. OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 88
      1. TABLE
    227. AUSTRALIA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 88
    228. SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING
    229. MARKET, BY SERVICES, 2022–2030 (USD MILLION) 88
    230. SOUTH KOREA:
    231. FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE
    232. SOUTH KOREA: FORMULATION DEVELOPMENT
    233. OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION, BY PHASE
      1. (USD MILLION) 89
    234. SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING
    235. MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 89
    236. SOUTH KOREA:
    237. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD
      1. MILLION) 90
    238. SOUTH KOREA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY END USER, 2022–2030 (USD MILLION) 90
    239. REST OF ASIA-PACIFIC:
    240. FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES, 2022–2030 (USD MILLION)
      1. 90
    241. REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR PREFORMULATION SERVICES, BY TYPE
      2. TABLE
    242. REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, FOR FORMULATION
      1. OPTIMIZATION, BY PHASE
    243. REST
    244. OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030
      1. (USD MILLION) 91
    245. REST OF ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING
    246. MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 92
    247. REST OF
    248. ASIA-PACIFIC: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 92
    249. MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT
    250. OUTSOURCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 93
      1. TABLE 164
    251. MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    252. MIDDLE EAST & AFRICA: FORMULATION
    253. DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE
      1. (USD MILLION) 93
    254. MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT
      1. OUTSOURCING MARKET, FOR FORMULATION OPTIMIZATION,
      2. BY PHASE 2022–2030
      3. (USD MILLION) 94
    255. MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT
    256. OUTSOURCING MARKET, BY DOSAGE FORM, 2022–2030 (USD MILLION) 94
      1. TABLE
    257. MIDDLE EAST & AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION,
    258. MIDDLE EAST & AFRICA: FORMULATION
    259. DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030 (USD MILLION) 95
    260. MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    261. MIDDLE EAST: FORMULATION DEVELOPMENT
    262. OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD
      2. MILLION) 96
    263. MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE
    264. MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM,
    265. MIDDLE EAST: FORMULATION DEVELOPMENT
    266. OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 97
      1. TABLE
    267. MIDDLE EAST: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 97
    268. AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. BY SERVICES, 2022–2030 (USD MILLION) 97
    269. AFRICA: FORMULATION
    270. DEVELOPMENT OUTSOURCING MARKET, FOR PREFORMULATION SERVICES, BY TYPE 2022–2030
      1. (USD MILLION) 98
    271. AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET,
      1. FOR FORMULATION OPTIMIZATION, BY PHASE 2022–2030
      2. (USD MILLION) 98
    272. AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY DOSAGE FORM,
    273. AFRICA: FORMULATION DEVELOPMENT
    274. OUTSOURCING MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 99
      1. TABLE
    275. AFRICA: FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022–2030
      1. (USD MILLION) 99
    276. MOST ACTIVE PLAYER IN THE GLOBAL FORMULATION DEVELOPMENT
      1. OUTSOURCING SERVICES 102
    277. ACQUISITION ACTIVITIES 103
      1. TABLE 184
      2. EXPANSION 104
    278. AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED: PRODUCTS/SERVICES
      1. OFFERED 119
    279. IRYSIS, INC.: PRODUCTS/SERVICES OFFERED 123
      1. TABLE
    280. CHARLES RIVER LABORATORIES INTERNATIONAL INC: PRODUCTS/SERVICES OFFERED 127
    281. CHARLES RIVER LABORATORIES: KEY DEVELOPMENTS 128
    282. INTERTEK
      1. GROUP PLC: PRODUCTS/SERVICES OFFERED 130
    283. INTERTEK GROUP PLC: KEY
      1. DEVELOPMENTS 131
    284. CATALENT INC: PRODUCTS/SERVICES OFFERED 133
      1. TABLE
    285. SYGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES OFFERED 137
    286. LABORATORY
      1. CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES OFFERED 141
    287. THERMO
      1. FISHER SCIENTIFIC: PRODUCTS/SERVICES OFFERED 144
    288. QUOTIENT SCIENCES:
      1. PRODUCTS/SERVICES OFFERED 147
    289. EMERGENT BIOSOLUTIONS INC: PRODUCTS/SERVICES
      1. OFFERED 149
    290. LIST OF FIGURES
    291. GLOBAL FORMULATION DEVELOPMENT
      1. OUTSOURCING MARKET STRUCTURE 18
    292. BOTTOM-UP AND TOP-DOWN APPROACHES
      1. 24
    293. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY SERVICES,
    294. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING
    295. MARKET, BY DOSAGE FORM, 2022 & 2030 (USD MILLION) 33
    296. GLOBAL FORMULATION
    297. DEVELOPMENT OUTSOURCING MARKET, BY APPLICATION, 2022 & 2030 (USD MILLION) 38
    298. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING MARKET, BY END USER, 2022
      1. & 2030 (USD MILLION) 43
    299. GLOBAL FORMULATION DEVELOPMENT OUTSOURCING
    300. MARKET SHARE, BY REGION, 2022 & 2030 (USD MILLION) 45
    301. GLOBAL FORMULATION
      1. DEVELOPMENT OUTSOURCING SERVICES MARKET, MARKET SHARE ANALYSIS, 2022 (%) 100
    302. MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL FORMULATION DEVELOPMENT
      1. OUTSOURCING SERVICES
      2. MARKET 101
    303. GLOBAL FORMULATION DEVELOPMENT
      1. OUTSOURCING SERVICES MARKET, COMPETITIVE LANDSCAPE 102
    304. SALES &
      1. OPERATING INCOME MARGIN 104
    305. R&D EXPENDITURE 104
      1. FIGURE 13
      2. AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED: SWOT ANALYSIS 122
      3. FIGURE 14
      4. IRISYS, INC: SWOT ANALYSIS 125
    306. CHARLES RIVER LABORATORIES INTERNATIONAL
      1. INC.: FINANCIAL OVERVIEW SNAPSHOT 126
    307. CHARLES RIVER LABORATORIES
      1. INTERNATIONAL INC: SWOT ANALYSIS 128
    308. INTERTEK GROUP PLC: FINANCIAL
      1. OVERVIEW SNAPSHOT 129
    309. INTERTEK GROUP PLC: SWOT ANALYSIS 131
      1. FIGURE
    310. CATALENT INC: FINANCIAL OVERVIEW SNAPSHOT 132
    311. CATALENT INC.: SWOT
      1. ANALYSIS 134
    312. SYGENE INTERNATIONAL LIMITED: FINANCIAL OVERVIEW SNAPSHOT
      1. 136
    313. SYGENE INTERNATIONAL LIMITED: SWOT ANALYSIS 139
      1. FIGURE 23
      2. LABORATORY CORPORATION OF AMERICA HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT 140
      3. FIGURE
    314. LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS 142
      1. FIGURE 25
      2. THERMOFISHER SCIENTIFIC: SWOT ANALYSIS 145
    315. QUOTIENT SCIENCES: SWOT
      1. ANALYSIS 148
    316. EMERGENT BIOSOLUTIONS INC.: SWOT ANALYSIS 150

    Market SegmentationFormulation Development Outsourcing Dosage Form Outlook (USD Billion, 2019-2030)

    • Injectable
    • Oral
    • Topical
    • Inhaled
    • Others

    Formulation Development Outsourcing Application Outlook (USD Billion, 2019-2030)

    • Oncology
    • Genetic Disorders
    • Neurology
    • Infectious Disease
    • Respiratory
    • Cardiovascular
    • Others

    Formulation Development Outsourcing Services Outlook (USD Billion, 2019-2030)

    • Pre Formulation Services
    • Formulation Optimization

    Formulation Development Outsourcing End User Outlook (USD Billion, 2019-2030)

    • Pharmaceutical and Biopharmaceutical
    • Government
    • Academic Institutes

    Formulation Development Outsourcing Regional Outlook (USD Billion, 2019-2030)

    • North America Outlook (USD Billion, 2019-2030)

      • North America Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • North America Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • North America Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • North America Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • US Outlook (USD Billion, 2019-2030)

      • US Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • US Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • US Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • US Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • CANADA Outlook (USD Billion, 2019-2030)

      • CANADA Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • CANADA Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • CANADA Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • CANADA Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

    • Europe Outlook (USD Billion, 2019-2030)

      • Europe Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Europe Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Europe Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Europe Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Germany Outlook (USD Billion, 2019-2030)

      • Germany Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Germany Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Germany Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Germany Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • France Outlook (USD Billion, 2019-2030)

      • France Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • France Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • France Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • France Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • UK Outlook (USD Billion, 2019-2030)

      • UK Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • UK Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • UK Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • UK Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • ITALY Outlook (USD Billion, 2019-2030)

      • ITALY Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • ITALY Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • ITALY Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • ITALY Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

     

      • SPAIN Outlook (USD Billion, 2019-2030)

      • Spain Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Spain Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Spain Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Spain Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Rest Of Europe Outlook (USD Billion, 2019-2030)

      • Rest Of Europe Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • REST OF EUROPE Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • REST OF EUROPE Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • REST OF EUROPE Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

    • Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Asia-Pacific Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Asia-Pacific Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Asia-Pacific Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Asia-Pacific Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • China Outlook (USD Billion, 2019-2030)

      • China Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • China Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • China Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • China Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Japan Outlook (USD Billion, 2019-2030)

      • Japan Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Japan Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Japan Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Japan Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • India Outlook (USD Billion, 2019-2030)

      • India Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • India Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • India Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • India Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Australia Outlook (USD Billion, 2019-2030)

      • Australia Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Australia Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Australia Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Australia Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Rest of Asia-Pacific Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Rest of Asia-Pacific Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Rest of Asia-Pacific Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Rest of Asia-Pacific Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

    • Rest of the World Outlook (USD Billion, 2019-2030)

      • Rest of the World Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Rest of the World Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Rest of the World Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Rest of the World Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

     

      • Middle East Outlook (USD Billion, 2019-2030)

      • Middle East Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Middle East Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Middle East Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Middle East Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Africa Outlook (USD Billion, 2019-2030)

      • Africa Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Africa Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Africa Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Africa Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes

      • Latin America Outlook (USD Billion, 2019-2030)

      • Latin America Formulation Development Outsourcing by Dosage Form
        • Injectable
        • Oral
        • Topical
        • Inhaled
        • Others
      • Latin America Formulation Development Outsourcing by Application
        • Oncology
        • Genetic Disorders
        • Neurology
        • Infectious Disease
        • Respiratory
        • Cardiovascular
        • Others
      • Latin America Formulation Development Outsourcing by Services
        • Pre Formulation Services
        • Formulation Optimization
      • Latin America Formulation Development Outsourcing by End User
        • Pharmaceutical and Biopharmaceutical
        • Government
        • Academic Institutes
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027